DarioHealth Announces Two New Studies Presented At ADA Scientific Sessions; Research Confirms Sustainable Behavior Change Over 12 Months With Dario Digital Platform; 31% Of Dario Members With Type 2 Diabetes Achieve Diabetes Remission; Analysis Includes Members Tracking GLP-1 Medication
Portfolio Pulse from Benzinga Newsdesk
DarioHealth presented two new studies at the ADA Scientific Sessions, showing that 31% of Dario members with Type 2 diabetes achieved remission using the Dario digital platform over 12 months. The research also included members tracking GLP-1 medication.
June 25, 2024 | 12:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
DarioHealth's new studies presented at the ADA Scientific Sessions demonstrate significant positive outcomes for Type 2 diabetes management using their digital platform, with 31% of members achieving remission over 12 months.
The positive results from the studies are likely to boost investor confidence in DarioHealth's digital platform, potentially leading to increased adoption and revenue growth. This news is highly relevant and important for DRIO's stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100